← TrialMatch
HomeTrials

Adapting rHIRE and Sleep Monitoring in Parkinson's Disease

Exercise is a primary intervention for symptom management in Parkinson's Disease (PD). However, challenges related to transportation, mobility, and socioeconomic factors often hinder consistent participation in exercise programs. To promote increased access and participation, remote exercise programs offer a promising

Condition(s)PARKINSON DISEASE (Disorder)
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryExercise is a primary intervention for symptom management in Parkinson's Disease (PD). However, challenges related to transportation, mobility, and socioeconomic factors often hinder consistent participation in exercise programs. To promote increased access and participation, remote exercise programs offer a promising solution. The investigators previously showed that laboratory-based, high-intensity resistance exercise improves sleep efficiency in individuals with PD in a randomized, controlled, clinical trial. The investigators aim to adapt this protocol for remote delivery and to evaluate the usability of a remote sleep-monitoring device in people with Parkinson's Disease (PwP). Guided by the IDEAS framework for digital health intervention design, the investigators will modify the exerc
Who can participateInclusion Criteria: * Currently residing in Colorado, USA * PD diagnosis per Movement Disorders Society Diagnostic Criteria * Requiring less than minimal assistance at home * Having internet access * Having a video-capable device Exclusion Criteria: * Uncontrolled cardiovascular disease or pulmonary disease * Musculoskeletal injuries * Participation in Parkinson's Disease community exercise programs more than 3 days a week * Contraindication to physical activity as determined by the Physical Activity Readiness Questionnaire (PAR-Q) * Fall risk defined by requiring \>20 seconds to complete the 5 times sit to stand test14 or high frequency of falls within the past year (≥ one fall per month) * Virtual Montreal Cognitive Assessment (MoCA) score ≥ 18 (performed at the eligibility visit)
Ages18 Years
SexAll
Lead sponsorUniversity of Colorado, Denver
LocationsAurora, Colorado, United States
Start date2026-03-05
NCT IDNCT07498296
Official listinghttps://clinicaltrials.gov/study/NCT07498296

🔍 Search all trials →